William Blair downgraded Lantheus (LNTH) to Market Perform from Outperform. Lantheus and Point (PNT) on Monday announced topline results from the Phase III SPLASH trial of PNT2002 vs. alternate novel hormone therapy in the pre-taxane metastatic castration-resistant prostate cancer setting, and while the trial met the primary endpoint, the two efficacy metrics underperformed vs. the firm’s expectations, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LNTH:
- Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
- GM upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- Lantheus initiated with an Outperform at TD Cowen
- Lantheus initiated with a Buy at Brookline
- Lantheus to Present at the Jefferies London Healthcare Conference
